Abstract
Although it has been recognized that thin strut cobalt chromium everolimus-eluting stent (EES; Xience) is associated with less target lesion failure, it has lower radial force, and it had failed to prove superiority to thick strut paclitaxel-eluting stent in diabetes in some studies. We speculated
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
